MAP2K7 and cholangiocarcinoma: The absence of approved KRAS-targeted therapies in cholangiocarcinoma limits treatment options to gemcitabine/cisplatin chemotherapy, though emerging strategies, including MEK and SHP2 inhibitors, are under investigation [18,19].